Psychotropic medications in pregnant women: Treatment dilemmas

Medical Journal of Australia

Volumn 169, Issue 8, 1998, Pages 428-431

  Austin, Marie Paule V ^a,b   Mitchell, Philip B ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; LITHIUM; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONGENITAL MALFORMATION; FEMALE; FETUS OUTCOME; HUMAN; NEWBORN DISEASE; PREGNANCY; PREMATURITY; RISK BENEFIT ANALYSIS;

EID: 0032547802     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb126837.x     Document Type: Article

References (41)

1. Pastuszak A, Koren G, Milich V, et al. Prospective assessment of pregnancy outcome following first-trimester exposure to benzodiazepines. In: Koren G, editor. Maternal and fetal toxicology. New York: Marcel Dekker, 1994: 77-88.
2. Doering PL, Steward RB. The extent and character of drug consumption during pregnancy. JAMA 1978; 239: 843-846.
3. Weissman MM, Olfson M. Depression in women: implications for health care research. Science 1995; 269: 799-801.
4. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998; 59 (Suppl 2): 18-28.
5. Hedegaard M, Henriksen TB, Sabroe S, et al. Psychological distress in pregnancy and preterm delivery. Br J Psychiatry 1993; 307: 234-238.
6. Lou HC, Hansen D, Nordenfoft M, et al. Prenatal Stressors of human life affect fetal brain development. Dev Med Child Neurol 1994; 36: 826-832.
7. Orr S, Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165-171.
8. Kallen B, Tandberg A. Lithium and pregnancy: a cohort study on manic-depressive women. Acta Psychiatr Scand 1983; 68: 134-139.
9. Kinney DK, Yurgelun-Todd DA, Levy DL, et al. Obstetrical complications in patients with bipolar disorder and their siblings. Psychiatry Res 1993; 48: 47-56.
10. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies Psychol Med 1996; 26: 279-287.
11. Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. New Eng J Med 1989; 320: 19-23.
12. Pastuszak A, Scick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA 1993; 269: 2246-2248.
13. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. New Engl J Med 1997; 336: 258-262.
14. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. New Engl J Med 1996; 335: 1010-1015.
15. Kulin N, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of new selective serotonin reuptake inhibitors: a prospective controlled multicentre study. JAMA 1998; 279: 609-610.
16. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci 1997; 22: 192-196.
17. Shearer WI, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Paediatr 1972; 81: 570-572.
18. Scolnik D, Nulman I, Rovet J, et al. The effects of phenytoin and carbamazepine monotherapy on infants' development. In: Koren G, editor. Maternal and fetal toxicology. A clinician guide. New York: Marcel Dekker, 1994: 45-58.
19. Laegreid L, Hagberg G, Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines: a prospective study. Neuropaediatr 1992; 23: 60-67.
20. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606.
21. McNeil TF. A prospective study of postpartum psychosis in a high risk group: relationship to demographic and psychiatric history characteristics. Acta Psychiatr Scand 1987; 73: 35-43.
22. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. Clin Psychopharmacol 1995; 15: 417-420.
23. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 1996; 10: 285-294.
24. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 1973; 2: 680.
25. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, Mass.: Publishing Services Group, 1977.
26. McElhatton PR. The effect of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8: 461-475.
27. Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy, I. Report from the Register of Lithium Babies. BMJ 1973; 2: 135-136.
28. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-150, correction; 271: 1485.
29. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530-533.
30. Schou M, Amdisen A. Lithium and the placenta [letter]. Am J Obstet Gynecol 1995; 122: 541.
31. Schou M. What happened to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54: 193-197.
32. Koren G, Pastuszak A, Jacobson S, et al. The safety of antidepressants in pregnancy. In: Koren G, editor. Maternal and fetal toxicology. A clinician guide. New York: Marcel Dekker, 1994: 59-76.
33. Mitchell PB, Parker G. Treatment of bipolar disorder. Med J Aust 1991; 155: 488-492.
34. Rosa F. Spina bifida in infants of women treated with carbamazepine during pregnancy. New Engl J Med 1991; 324: 674-677.
35. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurol 1992; 42 (suppl 5): 119-125.
36. Thisted E, Ebbesen F. Malformations, withdrawal manifestations and hypoglycemia after exposure to valproate in utero. Arch Dis Childhood 1993; 69: 288-291.
37. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenicity effects of phenothiazines in human beings. Teratology 1997; 15: 57-64.
38. Hanson JW, Oakley GP Jr. Haloperidol and limb deformity [letter]. JAMA 1975; 231: 26.
39. Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidum. J Clin Pharmacol 1969; 9: 224-237.
40. Auebach JG, Hans SL, Marcus J, et al. Maternal psychotropic medication and neonatal behaviour. Neurotoxicol Teratol 1992; 14: 399-406.
41. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry 1984; 25: 32-38.